140 related articles for article (PubMed ID: 33395066)
1. Prolonged benefit to pembrolizumab in anaplastic oligodendroglioma patient with mismatch repair deficiency: a case report.
Padovan M; Caccese M; Zagonel V; Lombardi G
Anticancer Drugs; 2021 Feb; 32(2):218-221. PubMed ID: 33395066
[TBL] [Abstract][Full Text] [Related]
2. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab.
Caccese M; Barbot M; Ceccato F; Padovan M; Gardiman MP; Fassan M; Denaro L; Emanuelli E; D'Avella D; Scaroni C; Zagonel V; Lombardi G
Anticancer Drugs; 2020 Feb; 31(2):199-204. PubMed ID: 31702999
[TBL] [Abstract][Full Text] [Related]
3. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
5. Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.
Casey RT; Giger O; Seetho I; Marker A; Pitfield D; Boyle LH; Gurnell M; Shaw A; Tischkowitz M; Maher ER; Chatterjee VK; Janowitz T; Mells G; Corrie P; Challis BG
Semin Oncol; 2018 Jun; 45(3):151-155. PubMed ID: 30262398
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.
Levin VA; Yung WK; Bruner J; Kyritsis A; Leeds N; Gleason MJ; Hess KR; Meyers CA; Ictech SA; Chang E; Maor MH
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):58-66. PubMed ID: 12007942
[TBL] [Abstract][Full Text] [Related]
7. The treatment of anaplastic oligodendrogliomas and mixed gliomas.
Kyritsis AP; Yung WK; Bruner J; Gleason MJ; Levin VA
Neurosurgery; 1993 Mar; 32(3):365-70; discussion 371. PubMed ID: 8455760
[TBL] [Abstract][Full Text] [Related]
8. Intravenous thrombolysis for ischemic stroke in recurrent oligodendroglioma: a case report.
Dafer RM; Paleologos N; Lynch D
J Stroke Cerebrovasc Dis; 2014; 23(5):1235-8. PubMed ID: 24103669
[TBL] [Abstract][Full Text] [Related]
9. Low-grade oligodendroglioma responds to chemotherapy.
Mason WP; Krol GS; DeAngelis LM
Neurology; 1996 Jan; 46(1):203-7. PubMed ID: 8559376
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.
Abrey LE; Childs BH; Paleologos N; Kaminer L; Rosenfeld S; Salzman D; Finlay JL; Gardner S; Peterson K; Hu W; Swinnen L; Bayer R; Forsyth P; Stewart D; Smith AM; Macdonald DR; Weaver S; Ramsey DA; Nimer SD; DeAngelis LM; Cairncross JG
J Neurooncol; 2003 Nov; 65(2):127-34. PubMed ID: 14686732
[TBL] [Abstract][Full Text] [Related]
12. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
Prasad V; Kaestner V; Mailankody S
JAMA Oncol; 2018 Feb; 4(2):157-158. PubMed ID: 29285544
[No Abstract] [Full Text] [Related]
13. Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
Chamberlain MC
Neurology; 2010 Jan; 74(2):181. PubMed ID: 20065257
[No Abstract] [Full Text] [Related]
14. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
Lemery S; Keegan P; Pazdur R
N Engl J Med; 2017 Oct; 377(15):1409-1412. PubMed ID: 29020592
[No Abstract] [Full Text] [Related]
15. [Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].
Chen G
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jan; 20(1):28-33. PubMed ID: 28105616
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for adrenocortical cancer.
Fojo AT
Semin Oncol; 2019 Feb; 46(1):1-2. PubMed ID: 30846053
[No Abstract] [Full Text] [Related]
17. Aggressive oligodendroglioma: a chemosensitive tumor.
Cairncross JG; Macdonald DR; Ramsay DA
Neurosurgery; 1992 Jul; 31(1):78-82. PubMed ID: 1641113
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review.
Da Fonseca CO; Masini M; Futuro D; Caetano R; Gattass CR; Quirico-Santos T
Surg Neurol; 2006 Dec; 66(6):611-5. PubMed ID: 17145324
[TBL] [Abstract][Full Text] [Related]
19. High-grade gliomas.
de Groot JF
Continuum (Minneap Minn); 2015 Apr; 21(2 Neuro-oncology):332-44. PubMed ID: 25837899
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological study of oligodendroglial tumors: the effectiveness of interferon beta, ACNU/MCNU, and radiation (IAR/IMR) for anaplastic tumors.
Wakabayashi T; Kajita Y; Hatano N; Thompson T; Nagasaka T; Yoshida J
Brain Tumor Pathol; 2000; 17(1):29-33. PubMed ID: 10982007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
